Efficacy of a Selective Binder of αβ Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2019 Apr 25

PMID 31013908

Citations 8

Authors

Andrea Sartori

Cristina Corno

Michelandrea De Cesare

Eugenio Scanziani

Lucia Minoli

Lucia Battistini

Franca Zanardi

Paola Perego

Affiliations

Soon will be listed here.

Abstract

Ovarian carcinoma, the most lethal gynecological cancer, is characterized by late diagnosis, with drug resistance limiting the efficacy of platinum-based therapy. Since some integrins are upregulated in cancer, including ovarian carcinoma, they represent a potential target for drug delivery. Receptor tyrosine kinases are also deregulated in cancer and their expression has been associated with drug resistance. Here, the antitumor effects of three conjugates possessing a selective binder of the extracellular portion of integrin αβ covalently linked to the tyrosine kinase inhibitor sunitinib were investigated in cisplatin-sensitive and -resistant ovarian carcinoma cells expressing both tyrosine kinase VEGFR2 and αβ at different levels. We found that one of the three compounds was active in inhibiting the growth of both drug-sensitive and -resistant cells in the micromolar range with a slightly increased potency in resistant cells as compared to sunitinib. The same compound markedly impaired cell migratory and invasive abilities and reduced paxillin phosphorylation. Antitumor activity studies in IGROV-1/Pt1 cells xenografted in nude mice revealed a striking activity of this conjugate versus sunitinib. Taken together, our results support the interest of integrin-targeted sunitinib conjugates for the treatment of drug-resistant tumors.

Citing Articles

Role of Cell Adhesion in Cancer Metastasis Formation: A Review.

Burcik D, Macko J, Podrojkova N, Demeterova J, Stano M, Orinak A ACS Omega. 2025; 10(6):5193-5213.

PMID: 39989825 PMC: 11840620. DOI: 10.1021/acsomega.4c08140.

Effects of cilengitide derivatives on TGF-β1-induced epithelial-to-mesenchymal transition and invasion in gefitinib-resistant non-small cell lung cancer cells.

Seo Y, Seo M, Kim J Front Pharmacol. 2023; 14:1277199.

PMID: 37927598 PMC: 10622769. DOI: 10.3389/fphar.2023.1277199.

Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine.

Guo C, Song C, Zhang J, Gao Y, Qi Y, Zhao Z Genes Dis. 2022; 9(3):668-681.

PMID: 35782973 PMC: 9243319. DOI: 10.1016/j.gendis.2020.11.017.

Nintedanib-Containing Dual Conjugates Targeting αβ Integrin and Tyrosine Kinase Receptors as Potential Antifibrotic Agents.

Bugatti K, Andreucci E, Monaco N, Battistini L, Peppicelli S, Ruzzolini J ACS Omega. 2022; 7(21):17658-17669.

PMID: 35664627 PMC: 9161413. DOI: 10.1021/acsomega.2c00535.

New 4-Aminoproline-Based Small Molecule Cyclopeptidomimetics as Potential Modulators of αβ Integrin.

Sartori A, Bugatti K, Portioli E, Baiula M, Casamassima I, Bruno A Molecules. 2021; 26(19).

PMID: 34641610 PMC: 8512764. DOI: 10.3390/molecules26196066.

References

Perego P, Gatti L, Righetti S, Beretta G, Carenini N, Corna E . Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer. 2003; 105(5):617-24. DOI: 10.1002/ijc.11140. View

Cannistra S . Cancer of the ovary. N Engl J Med. 2004; 351(24):2519-29. DOI: 10.1056/NEJMra041842. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Zanardi F, Burreddu P, Rassu G, Auzzas L, Battistini L, Curti C . Discovery of subnanomolar arginine-glycine-aspartate-based alphaVbeta3/alphaVbeta5 integrin binders embedding 4-aminoproline residues. J Med Chem. 2008; 51(6):1771-82. DOI: 10.1021/jm701214z. View

Somanath P, Malinin N, Byzova T . Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis. 2009; 12(2):177-85. PMC: 2863048. DOI: 10.1007/s10456-009-9141-9. View

Bast Jr R, Hennessy B, Mills G . The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9(6):415-28. PMC: 2814299. DOI: 10.1038/nrc2644. View

Cossa G, Gatti L, Zunino F, Perego P . Strategies to improve the efficacy of platinum compounds. Curr Med Chem. 2009; 16(19):2355-65. DOI: 10.2174/092986709788682083. View

Battistini L, Burreddu P, Carta P, Rassu G, Auzzas L, Curti C . 4-Aminoproline-based arginine-glycine-aspartate integrin binders with exposed ligation points: practical in-solution synthesis, conjugation and binding affinity evaluation. Org Biomol Chem. 2009; 7(23):4924-35. DOI: 10.1039/b914836a. View

Dolman M, Harmsen S, Pieters E, Sparidans R, Lacombe M, Szokol B . Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. Int J Nanomedicine. 2012; 7:417-33. PMC: 3273977. DOI: 10.2147/IJN.S26485. View

10.

Pilkington-Miksa M, Arosio D, Battistini L, Belvisi L, De Matteo M, Vasile F . Design, synthesis, and biological evaluation of novel cRGD-paclitaxel conjugates for integrin-assisted drug delivery. Bioconjug Chem. 2012; 23(8):1610-22. DOI: 10.1021/bc300164t. View

11.

Cossa G, Gatti L, Cassinelli G, Lanzi C, Zaffaroni N, Perego P . Modulation of sensitivity to antitumor agents by targeting the MAPK survival pathway. Curr Pharm Des. 2012; 19(5):883-94. View

12.

Colombo R, Mingozzi M, Belvisi L, Arosio D, Piarulli U, Carenini N . Synthesis and biological evaluation (in vitro and in vivo) of cyclic arginine-glycine-aspartate (RGD) peptidomimetic-paclitaxel conjugates targeting integrin αVβ3. J Med Chem. 2012; 55(23):10460-74. DOI: 10.1021/jm301058f. View

13.

Cassinelli G, Zuco V, Gatti L, Lanzi C, Zaffaroni N, Colombo D . Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem. 2013; 20(15):1923-45. DOI: 10.2174/09298673113209990106. View

14.

Jeltsch M, Leppanen V, Saharinen P, Alitalo K . Receptor tyrosine kinase-mediated angiogenesis. Cold Spring Harb Perspect Biol. 2013; 5(9). PMC: 3753715. DOI: 10.1101/cshperspect.a009183. View

15.

Cossa G, Lanzi C, Cassinelli G, Carenini N, Arrighetti N, Gatti L . Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells. Cancer Lett. 2014; 347(2):212-24. DOI: 10.1016/j.canlet.2014.02.016. View

16.

Imbulgoda A, Heng D, Kollmannsberger C . Sunitinib in the treatment of advanced solid tumors. Recent Results Cancer Res. 2014; 201:165-84. DOI: 10.1007/978-3-642-54490-3_9. View

17.

Ouyang W, Xu L, Huang Z, Guo J, Cai J, Gao X . Role of HER family members in predicting prognoses in epithelial ovarian cancer: a meta-analysis. Tumori. 2015; 101(6):595-602. DOI: 10.5301/tj.5000343. View

18.

Bianchi A, Arosio D, Perego P, De Cesare M, Carenini N, Zaffaroni N . Design, synthesis and biological evaluation of novel dimeric and tetrameric cRGD-paclitaxel conjugates for integrin-assisted drug delivery. Org Biomol Chem. 2015; 13(27):7530-41. DOI: 10.1039/c5ob00497g. View

19.

Dal Corso A, Pignataro L, Belvisi L, Gennari C . αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology. Curr Top Med Chem. 2015; 16(3):314-29. DOI: 10.2174/1568026615666150701114343. View

20.

Hao Z, Sadek I . Sunitinib: the antiangiogenic effects and beyond. Onco Targets Ther. 2016; 9:5495-505. PMC: 5021055. DOI: 10.2147/OTT.S112242. View